Literature DB >> 24505566

The Author Response: Serum anti-Müllerian hormone levels and phenotypes of polycystic ovary syndrome.

Hye Ok Kim1.   

Abstract

Entities:  

Year:  2013        PMID: 24505566      PMCID: PMC3913899          DOI: 10.5653/cerm.2013.40.4.178

Source DB:  PubMed          Journal:  Clin Exp Reprod Med        ISSN: 2093-8896


× No keyword cloud information.
Reply: We recently published an original article entitled "Can high serum Anti-Müllerian hormone (AMH) levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?" [1]. There are numerous reports on high serum AMH levels in patients with PCOS, and their serum AMH levels are much variable. We were curious about the possibility that high serum AMH levels are correlated with the phenotypes of PCOS and metabolic derangement. We did not find any significant difference according to the phenotypes of PCOS in the non-obese group. The correspondents pointed out that our result is different from a recent report from Sahmay et al. [2]. The study of Sahmay et al. [2] was a cross-sectional retrospective study and included 251 women with PCOS. They concluded that AMH levels seem to play a diagnostic role in determining the severity of PCOS. There are differences in this study population, who had over 75% hyperandrogenism (HA) and had a similar body mass index (BMI) among the groups. Our study group showed a relatively low percentage of HA (36%, 59/175) and significantly higher BMI in the PCOS patients who had 3 diagnostic criteria (anovulation+HA+polycystic morphology). PCOS women without HA are more common in Korea and are less likely to have metabolic dysfunction, insulin resistance, and elevated blood pressure [3]. PCOS without HA could be a mild phenotype of PCOS [3]. In another study, it was reported that Chinese women with PCOS showed lower rates of HA, hirsutism, obesity, and insulin resistance [4]. Furthermore, obese women have lower AMH levels compared to non-obese women [5]. Recently, it has been recommended that the follicle number per ovary for the diagnosis of polycystic ovary morphology be set at ≥25 [6]. The thresholds used to define follicle excess, particularly in diverse populations must be reconsidered. We suggest that ethnicity might contribute to variation. We value the comments of the correspondents and plan to perform a larger scale study to clarify these results.
  6 in total

1.  Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.

Authors:  Sezai Sahmay; Nil Atakul; Mahmut Oncul; Abdullah Tuten; Begum Aydogan; Hakan Seyisoglu
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-06-24       Impact factor: 2.435

2.  Association of anti-mullerian hormone levels with obesity in late reproductive-age women.

Authors:  Ellen W Freeman; Clarisa R Gracia; Mary D Sammel; Hui Lin; Lony Chong-Leong Lim; Jerome F Strauss
Journal:  Fertil Steril       Date:  2006-11-15       Impact factor: 7.329

3.  Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.

Authors:  Soo Jin Chae; Jin Ju Kim; Young Min Choi; Kyu Ri Hwang; Byung Chul Jee; Seung Yup Ku; Chang Suk Suh; Seok Hyun Kim; Jung Gu Kim; Shin Yong Moon
Journal:  Hum Reprod       Date:  2008-06-24       Impact factor: 6.918

4.  Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.

Authors:  Hong Yuan Zhang; Cheng Xiu Guo; Fu Fan Zhu; Peng Peng Qu; Wan Jun Lin; Jing Xiong
Journal:  Arch Gynecol Obstet       Date:  2012-10-30       Impact factor: 2.344

5.  Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.

Authors:  Didier Dewailly; Marla E Lujan; Enrico Carmina; Marcelle I Cedars; Joop Laven; Robert J Norman; Héctor F Escobar-Morreale
Journal:  Hum Reprod Update       Date:  2013-12-16       Impact factor: 15.610

6.  Can high serum anti-Müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Authors:  Yu Im Hwang; Na Young Sung; Hwa Seon Koo; Sun Hwa Cha; Chan Woo Park; Jin Yeong Kim; Kwang Moon Yang; In Ok Song; Mi Kyoung Koong; Inn Soo Kang; Hye Ok Kim
Journal:  Clin Exp Reprod Med       Date:  2013-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.